Tumor Necrosis Factor News and Research

RSS

Researchers identify new combination therapy that promotes cancer cell death

Researchers at the University of Pennsylvania School of Medicine identified a combination therapy as a way to sensitize resistant human cancer cells to a treatment currently being tested in clinical trials They propose that the therapy may help to selectively eliminate cancer cells while leaving healthy cells intact, providing a cancer treatment with fewer side effects.

17 Jul 2007

Scientists take exciting approach for attacking cancers

A new study identifies a combination therapy that may sensitize human cancer cells to a promising treatment currently being used in clinical trials.

10 Jul 2007

Omega-3 polyunsaturated fatty acids protect against retinopathy

Omega-3 polyunsaturated fatty acids protect against the development and progression of retinopathy, a deterioration of the retina, in mice.

26 Jun 2007

Extended exposure to the psoriasis medication etanercept reduces psoriasis severity without increased adverse events

Extended exposure to the psoriasis medication etanercept does not appear to cause more infections or adverse events than placebo, and improvements in several measures of disease severity were observed for up to 96 weeks of therapy, according to a study in the June issue of Archives of Dermatology.

19 Jun 2007

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

Abbott has announced it has simultaneously submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA (adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the U.S. and juvenile idiopathic arthritis (JIA) in the European Union (EU).

9 May 2007

Facts about rheumatoid arthritis and aging

For the better part of three decades, Sherrie Kossoudji has endeavored each day to manage the inflammation, chronic pain, tight joints and other types of physical strife caused by rheumatoid arthritis.

8 May 2007

Infliximab fails to improve chronic obstructive pulmonary disease symptoms

A promising anti-inflammatory drug failed to improve symptoms of moderate to severe chronic obstructive pulmonary disease, or COPD, in a large, multi-center trial.

2 May 2007

Adalimumab shows potential for Crohn's disease

A study led by Mayo Clinic found that adalimumab (HUMIRA) is an effective treatment for adults with Crohn's disease who do not respond to infliximab (REMICADE) therapy.

2 May 2007

Professor Marc Feldmann wins top lifetime achievement award

The academic who developed a treatment for autoimmune diseases that has helped millions of patients around the world last night received a prestigious lifetime achievement award at this year's European Inventor of the Year awards.

24 Apr 2007

Abbott opens biotech facility in Puerto Rico

"This new facility is a key milestone for Abbott as we move to focus our resources and future growth on biologic and potent-drug manufacturing," said Lawrence Kraus, vice president of manufacturing, global pharmaceutical operations, Abbott.

11 Apr 2007

Efficacy of Guanilib confirmed for inflammatory bowel disease

Callisto Pharmaceuticals has announced additional data confirming efficacy of Guanilib, a first-in-class compound currently being developed for the treatment of inflammatory bowel disease (IBD), in two different standard animal models of experimental colitis.

7 Apr 2007

We need to balance out our intake of omega-6 and omega-3 fatty acids

A new study suggests that people whose diets contain dramatically more of one kind of polyunsaturated fatty acid than another may be at greater risk for both clinical depression and certain inflammatory diseases.

3 Apr 2007

Decoy receptor 3 expressed in rheumatic synovial fibroblasts protects the cells against Fas-induced apoptosis

A complex autoimmune disease, rheumatoid arthritis (RA) is characterized by chronic inflammation and progressive joint damage. This process begins with hyperplasia, or excessive increase in size and thickness, of synovial tissue. Along with provoking cartilage and bone destruction, this abnormal tissue growth is resistant to apoptosis, the natural cell death vital to the generation of healthy new cells.

30 Mar 2007

New Crohn's disease treatment Humira promises to reduce symptoms

The Food and Drug Administration (FDA) in the United States has given it's approval for the use of the drug Humira (adalimumab) to treat adults suffering from Crohn's disease.

28 Feb 2007

FDA approves Humira (adalimumab) for Crohn's disease

The U.S. Food and Drug Administration (FDA) today approved Humira (adalimumab) to treat adult patients with moderately to severely active Crohn's disease, a chronic inflammatory disease of the intestines, which affects an estimated one million Americans.

27 Feb 2007